McClellan To Lead June 13 CMS Forum On Drug Data Strategies
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA and AHRQ officials will discuss ways Medicare data could help improve medical decisions. The Drug Data Strategy plan combines Part D drug data with Parts A and B medical treatment data.
You may also be interested in...
FDA Advisory Committees To Help Decide Medicare Rx Data Research Agenda
Claims data collected on prescriptions filled through the Medicare drug benefit will be used by outside groups to produce evidence on drugs' safety and effectiveness. FDA advisory committees, AHRQ and IoM could help determine study priorities, CMS says.
Editor's Note: Please Help Pink Sheet Serve You Best
Please take our brief reader survey to help us better understand your content and delivery needs.
Editor’s Choice: Notable Pink Sheet Articles From Q3
A must-read selection of intriguing and popular articles posted in the Pink Sheet over the past three months.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: